IRIS
NUVOLONE, MARIO ULISSE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.314
EU - Europa 874
AS - Asia 533
AF - Africa 2
Continente sconosciuto - Info sul continente non disponibili 1
OC - Oceania 1
Totale 2.725
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.310
CN - Cina 521
IE - Irlanda 504
FI - Finlandia 123
DE - Germania 86
UA - Ucraina 50
IT - Italia 45
SE - Svezia 17
BE - Belgio 11
FR - Francia 11
AT - Austria 8
GB - Regno Unito 8
CA - Canada 4
IN - India 4
IR - Iran 4
NO - Norvegia 4
HK - Hong Kong 2
MU - Mauritius 2
RU - Federazione Russa 2
AU - Australia 1
CH - Svizzera 1
ES - Italia 1
EU - Europa 1
LU - Lussemburgo 1
MY - Malesia 1
NL - Olanda 1
RO - Romania 1
TR - Turchia 1
Totale 2.725
Salva come PNG Salva come JPEG
Città #
Dublin 504
Chandler 349
Nanjing 158
Ashburn 122
Jacksonville 93
Helsinki 80
Princeton 73
Lawrence 68
Beijing 61
Wilmington 57
Medford 53
Nanchang 53
Ann Arbor 52
Shenyang 40
Jiaxing 38
Shanghai 36
Hebei 35
Changsha 32
Hangzhou 26
New York 20
Tianjin 20
Woodbridge 16
Norwalk 15
Redwood City 15
Pavia 14
Brussels 11
Seattle 10
Fairfield 9
Milan 9
Washington 9
Los Angeles 6
Tamm 6
Boardman 5
Falkenstein 5
Falls Church 4
Pune 4
Zhengzhou 4
Catania 3
Ningbo 3
Verona 3
Vienna 3
Hanover 2
Nagold 2
Orange 2
Palermo 2
Redmond 2
Toronto 2
Andover 1
Ardabil 1
Auburn Hills 1
Baltimore 1
Berlin 1
Borås 1
Changchun 1
Des Moines 1
Fuzhou 1
Houston 1
Jinan 1
Kemerovo 1
Kish 1
Kunming 1
Las Vegas 1
London 1
Lugano 1
Luxembourg 1
Magenta 1
Markham 1
Richmond 1
Rockville 1
Sacramento 1
San Francisco 1
Sassari 1
Selangor 1
Shiraz 1
Simi Valley 1
Sydney 1
Taizhou 1
Zanjan 1
Totale 2.167
Salva come PNG Salva come JPEG
Nome #
Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a matched case-control study on 174 patients 80
Bone marrow amyloidosis. 78
Treatment of patients with advanced cardiac AL amyloidosis with oral melphalan, dexamethasone, and thalidomide 75
A phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis 73
Identification of Amyloidogenic Light Chains Requires the Combination of Serum-Free Light Chain Assay with Immunofixation of Serum and Urine 66
Correlation between serum concentrations of N-terminal natriuretic peptide type B (NT-proBNP) and troponin-I (TnI) in AL amyloidosis 65
Circulating free light chain measurement in the diagnosis, prognostic assessment and evaluation of response of AL amyloidosis: comparison of Freelite and N latex FLC assays 63
Amyloid Diseases at the Molecular Level: General Overview and Focus on AL Amyloidosis 57
Amyloid diseases at the molecular level: general overview and focus on AL amyloidosis. 56
Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib and thalidomide 54
Identification and quantification of urinary monoclonal proteins by capillary electrophoresis in AL amyloidosis 54
Expanding the spectrum of systemic amyloid diseases: a new hint from the kidney 50
Cystatin F is a biomarker of prion pathogenesis in mice 50
Severity and reversibility of cardiac dysfunction and residual concentration of amyloidogenic light chain predict overall survival of patients with AL amyloidosis who attain complete response 50
Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis 49
Urinary albumin to creatinine ratio in diagnosis and risk stratification of renal AL amyloidosis 49
Regulated expression of amyloidogenic immunoglobulin light chains in mice 46
Emerging therapeutic targets currently under investigation for the treatment of systemic amyloidosis 46
Prognostication of survival and progression to dialysis in AA amyloidosis 45
Patterns of relapse after upfront bortezomib therapy in AL amyloidosis 44
Extended characterization of the novel co-isogenic C57BL/6J Prnp−/− mouse line 44
Patients with AL amyloidosis and low free light-chain burden have distinct clinical features and outcome 43
Liver involvement as the hallmark of aggressive disease in light chain amyloidosis: distinctive clinical features and role of light chain type in 225 patients 42
ATR-FTIR spectroscopy supported by multivariate analysis for the characterization of adipose tissue aspirates from patients affected by systemic amyloidosis 40
Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach 39
Altered monoaminergic systems and depressive-like behavior in congenic prion protein knock-out mice 39
The complex PrPc-Fyn couples human oligomeric Aβ with pathological tau changes in Alzheimer's disease 38
Structure-based drug design identifies polythiophenes as antiprion compounds 37
Simple, reliable detection of amyloid in fat aspirates using the fluorescent dye FSB: Prospective study in 206 patients 37
High rate of profound clonal and renal responses with daratumumab treatment in heavily pre-treated patients with light chain (AL) amyloidosis and high bone marrow plasma cell infiltrate 37
Efficient amyloid A clearance in the absence of immunoglobulins and complement factors 36
Bioelectrical impedance vector analysis-derived phase angle predicts survival in patients with systemic immunoglobulin light-chain amyloidosis 36
Minimal residual disease negativity by next-generation flow cytometry is associated with improved organ response in AL amyloidosis 36
The prion protein is an agonistic ligand of the G protein-coupled receptor Adgrg6 35
The Role of the NADPH Oxidase NOX2 in Prion Pathogenesis 33
Cells and prions: A license to replicate 32
Efficient generation of multipotent mesenchymal stem cells from umbilical cord blood in stroma-free liquid culture 32
Nonlymphoplasmacytic lymphomas associated with light-chain amyloidosis 32
Indicators of profound hematologic response in AL amyloidosis: complete response remains the goal of therapy 32
Treating Protein Misfolding Diseases: Therapeutic Successes Against Systemic Amyloidoses 31
Genome-wide transcriptomics identifies an early preclinical signature of prion infection 31
Systemic amyloidosis: novel therapies and role of biomarkers 30
A neuroprotective role for microglia in prion diseases 30
Bone marrow microenvironment in light-chain amyloidosis: In vitro expansion and characterization of mesenchymal stromal cells 30
Prion pathogenesis is unaltered in the absence of SIRPα-mediated "don't-eat-me" signaling 29
Daratumumab in light chain deposition disease: Rapid and profound hematologic response preserves kidney function 29
Prion pathogenesis in the absence of NLRP3/ASC inflammasomes 28
Prion protein and Ab-related synaptic toxicity impairment 28
Mass spectrometry characterization of light chain fragmentation sites in cardiac AL amyloidosis:insights into the timing of proteolysis 28
Novel challenges in the management of immunoglobulin light chain amyloidosis: from the bench to the bedside 28
Strictly co-isogenic C57BL/6J-Prnp-/- mice: A rigorous resource for prion science 27
Prospective urinary albumin/creatinine ratio for diagnosis, staging, and organ response assessment in renal AL amyloidosis: Results from a large cohort of patients 27
The Priority position paper: Protecting Europe's food chain from prions 26
Single-molecule real-time sequencing of the M protein: Toward personalized medicine in monoclonal gammopathies 25
Sequential response-driven bortezomib-based therapy followed by autologous stem cell transplant in AL amyloidosis 25
A complicated evaluation of the response to the therapy in a patient with light chain deposition disease 24
Prion pathogenesis is unaltered in a mouse strain with a permeable blood-brain barrier 24
A safety review of drug treatments for patients with systemic immunoglobulin light chain (AL) amyloidosis 24
The workings of the amyloid diseases. 23
Oral Therapy for the Treatment of Transthyretin-Related Amyloid Cardiomyopathy 22
Bioelectrical impedance vector analysis-derived phase angle predicts survival in patients with systemic immunoglobulin light-chain amyloidosis 22
An N-glycosylation hotspot in immunoglobulin κ light chains is associated with AL amyloidosis 22
Analysis of cyclin D1 mRNA expression levels in plasma cell dyscrasias: A systematic review of published literature 22
The immunobiology of prion diseases 22
Free light measurement identifies relapse and prompts to reconsider amyloid typing in a patient with AL amyloidosis 20
Clonal biomarkers for diagnosis and response to treatment assessment in light chain amyloidosis: The role of the laboratory 20
SIRPα polymorphisms, but not the prion protein, control phagocytosis of apoptotic cells 20
Protease-sensitive regions in amyloid light chains: what a common pattern of fragmentation across organs suggests about aggregation 20
A case of monoclonal gammopathy of renal significance 20
Identification of genes for normalization of RT-qPCR gene expression data: A review of published literature 19
Redirecting proteoxicity 19
A nationwide prospective registry of bortezomib-based therapy in light chain (AL) amyloidosis 19
Cryo-EM structure of ex vivo fibrils associated with extreme AA amyloidosis prevalence in a cat shelter 18
Targeting Amyloid Fibrils by Passive Immunotherapy in Systemic Amyloidosis 18
Management of the elderly patient with AL amyloidosis 18
Tumor cells in light-chain amyloidosis and myeloma show distinct transcriptional rewiring of normal plasma cell development 16
New Insights Into a Multifaceted Disease 15
Evaluation of response to treatment in a patient with light chain amyloidosis and low free light chain burden 14
Improved outcomes for kidney transplantation in AL amyloidosis: impact on practice 14
Lymphocyte activation gene 3 (Lag3) expression is increased in prion infections but does not modify disease progression 13
Pomalidomide and dexamethasone grant rapid haematologic responses in patients with relapsed and refractory AL amyloidosis: a European retrospective series of 153 patients 13
The Interaction of the Tumor Suppressor FAM46C with p62 and FNDC3 Proteins Integrates Protein and Secretory Homeostasis 13
Brain aging is faithfully modelled in organotypic brain slices and accelerated by prions 12
Analysis of co-isogenic prion protein deficient mice reveals behavioral deficits, learning impairment, and enhanced hippocampal excitability 10
A Strategy for the Selection of RT-qPCR Reference Genes Based on Publicly Available Transcriptomic Datasets 8
Glial activation in prion diseases is selectively triggered by neuronal PrPSc 7
Transthyretin-associated familial amyloid polyneuropathy - current and emerging therapies 6
Renal amyloidoses 6
null 6
Tau Exon 10 Inclusion by PrPC through Downregulating GSK3β Activity 5
La medicina di laboratorio: Gli Specialisti di domani 5
Scaling analysis reveals the mechanism and rates of prion replication in vivo 4
Totale 2.885
Salva come PNG Salva come JPEG
Categoria #
all - tutte 12.649
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 12.649
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201915 0 0 0 0 0 0 0 0 0 8 3 4
2019/2020555 166 257 0 10 3 10 1 14 15 36 20 23
2020/2021165 15 9 6 15 7 17 11 42 8 17 16 2
2021/2022280 3 5 3 0 8 9 6 26 20 5 40 155
2022/20231.175 119 89 20 66 92 104 25 51 563 6 29 11
2023/2024428 59 103 25 28 46 102 16 26 6 17 0 0
Totale 2.885